Bristol-Myers Squibb news from FiercePharma
NewsBMS: Buyer or buyout target?
Market-watchers love to speculate. Their latest topic? Bristol-Myers Squibb, which has been paring away its "non-core" businesses over the last few months. Most recently, Bristol agreed to Read more...
Bristol profits leap on Plavix sales
Bristol-Myers Squibb's third-quarter results show what one big drug can do. Net income more than doubled to $858 million on revenues of $5.1 billion--and Plavix was the biggest reason. Third quarter Read more...
BMS cancer med could earn $500M
Analysts are rubbing their hands over the FDA's approval of Ixempra, a Bristol-Myers Squibb breast cancer treatment, predicting $500 million in annual sales by 2010. The drug got the agency's nod as Read more...
| Press ReleasesBristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular DiseBristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease First-in-Class Compound Designed to Improve Clinical Outcomes Read more... PRESS RELEASE: Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical Imaging for Approximately $525 Million Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical Imaging for Approximately $525 Million NEW YORK, Dec. 17 -- Bristol-Myers Squibb Company (NYSE: BMY) and Avista Capital Read more... PRESS RELEASE: Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community Expects Productivity Transformation Initiative to Generate Pre-Tax Read more... PRESS RELEASE: Bristol-Myers Squibb to Webcast December 5 Business Update Bristol-Myers Squibb to Webcast December 5 Business Update NEW YORK, Nov. 28 -- Bristol-Myers Squibb Company will provide a business update to the investment community on Wednesday, December 5 from Read more... PRESS RELEASE: Bristol-Myers Squibb Ends Cancer Drug Deal with Pierre Fabre Bristol-Myers Squibb Ends Cancer Drug Deal with Pierre Fabre PRINCETON, N.J., and PARIS, Nov. 23 -- Bristol- Myers Squibb Company and Pierre Fabre Medicament reported today that they are terminating Read more... |
Get more Bristol-Myers Squibb coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight